EBR Systems, Inc.
Price, market cap and P/E appear here once daily prices are connected.
About EBR Systems
Surgical & Medical Instruments & Apparatus, SIC 3841
EBR Systems, Inc. develops implantable cardiac pacing devices designed to stimulate heart tissue without conventional leads. The company’s core offering is the WiSE CRT System, an implantable system providing cardiac resynchronization therapy for heart rhythm disorders. This technology converts ultrasound energy into electrical pulses to stimulate the left ventricle in conjunction with a co-implanted right ventricular pacing device. The product targets adult patients requiring cardiac resynchronization who cannot use standard lead systems due to previous failed implantations or high complication risks during upgrades.
The company operates primarily within the United States medical technology sector and targets key, high-volume hospitals and medical facilities. It also plans targeted expansion into select international healthcare markets following regulatory and reimbursement assessments. EBR Systems maintains its principal executive offices and corporate headquarters in Sunnyvale, California.
Summary of the business section of EBR Systems's latest annual report, written by StockData.
Company profile
Company
- Legal name
- EBR Systems, Inc.
- Founded
- 2003
- Headquarters
- Sunnyvale, CA
- Address
- 480 Oakmead Parkway 94085
- Phone
- (408) 720-1906
- Website
- ebrsystemsinc.com
- Employees
- 135, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Tempe, Arizona
Stock & identifiers
- Ticker
- NONE.
- Other tickers
- EBRCZ
- Shares outstanding
- 75M, Aug 11, 2026
- Public float
- $351.00M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, May 11, 2026
- SEC CIK
- 1347123
- EIN
- 57-1164669
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John McCutcheon | President and CEO, Director | 109,100 |
| Gary W. Doherty | Chief Financial Officer | – |
| Michael Hendricksen | Chief Operating Officer | – |
| Bronwyn Evans | Director | 235,158 |
| Trevor J. Moody | Director | – |
| Karen Drexler | Director | – |
| Christopher Nave | Director | 0 |
| Allan R. Will | Director | 6,595,724 |
| David Steinhaus | Director | – |
Employees
Headcount reported in annual reports
“we had 135 full-time employees including 90 in research and development and 45 in selling, general and administrative.”